Ajinomoto Bio-Pharma Services, a provider of biopharmaceutical contract development and manufacturing services, and Revance Therapeutics Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, have signed a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for Injection.
 
DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review. Aji Bio-Pharma will serve as a dual supply source and provide drug product manufacturing services for Revance at the company’s aseptic manufacturing facility in San Diego, California.
 
“We are excited to partner with Revance and their efforts to establish a new standard in aesthetic and therapeutic neuromodulator offerings,” said Jean-Baptiste Agnus, VP of sales at Ajinomoto Bio-Pharma Services. “This partnership underscores our commitment to be a leading, trusted, innovative partner to our clients and reinforces our company mission to improve the health of humankind.”
 
“We are delighted to be partnering with Aji Bio-Pharma for the production of our innovative product and bolstering our supply chain resiliency,” added Brian Blagg, vice president, Engineering & Supply Chain at Revance. “Aji Bio-Pharma’s manufacturing infrastructure, long-standing experience and customer-centric service, were important to this collaboration.”